Rameda receives export requests for its COVID-19 drug Anviziram
The pharmaceuticals firm awaits the Egyptian Ministry of Health’s approval to export…
Rameda starts manufacturing of generic Anviziram for COVID-19 treatment
EDA also grants approval for Rameda to begin manufacturing intravenous Remedisivir vials
Rameda reports 22% top line, 196% net income growth in Q1 2020
Company faced COVID-19 crisis through targeted policies ensuring it continuously provides patients…
Rameda offers free home delivery of prescription drugs amid Covid-19 outbreak
Initiative to last for three months over three phases
Rameda acquires one of best-selling generic NSAIDs in Egypt
According to IQVIA, a world leader in advanced data analytics covering pharmaceutical…
Rameda Reports double-digit topline growth in FY19
Plans to launch at least 12 new molecules each year in the…
Rameda plans to introduce new drugs for the digestive system, diabetes, nerves, and antibiotics
New acquisitions opportunities to produce pharmaceutical products that the company does not…
Rameda targets stock market debut in 4Q 2019
Company to use IPO to fund opportunistic acquisition of pharmaceutical companies